Intrinsiqq
Ascentage Pharma Group International logo

Ascentage Pharma Group International

AAPG

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap¥7.11B
EPS-¥13.96
P/E-0.86
P/FCF-5.92
EV/EBITDA-5.53
FCF Yield–
Div. Yield–
Net Debt/FCF0.4x
Ascentage Pharma Group International intrinsic value
52-Week Range
$11.97$32.88

Profitability & Returns

Revenue (TTM)

¥574M

▼ -41.5% YoY

Net Income (TTM)

-¥1.24B

▼ -206.4% YoY

Op. Margin

-208.61%

▼ -170.9pp YoY

ROIC

-36.00%

▼ -20.7pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-¥1.20B

▼ -785.9% YoY

Op. Cash Flow (TTM)

-¥1.17B

▼ -954.4% YoY

Net Debt

-¥485M

Net Cash Position

Cash & Equiv.

¥2.46B

3Y CAGR: +39.9%

Continue Research

Peers

Biotechnology · Pick stocks to compare with AAPG

CompareIntrinsic value
NAVA.XOSLNavamedic ASA
€0.95-3.85%29
ELN.XMILEL.En. S.p.A.
€16.12-2.01%53
FAE.XMADFaes Farma, S.A.
€4.83-1.13%65
PIHLIS.XHELPihlajalinna Oyj
€8.30-0.95%63
LSBCFLakeShore Biopharma Co., Ltd
No recent price26
STIL.XSTOStille AB
€21.85-2.24%59
IBAB.XBRUIon Beam Applications SA
€16.06-1.59%46
VETO.XPARVetoquinol SA
€85.70-0.70%63

Ascentage Pharma Group International (AAPG) in four numbers

Fair value (revenue)
$2.30
Price $11.97 is 421% above it.
Intrinsic Value
Quality score
40/100
Best check: revenue growth, 39.9%. Weakest: return on capital, -36.0%.
Quality
Dividend
None
No dividend in the company filings we hold.
Dividends
P/E
-0.86
Negative: a loss over the last twelve months. Price to free cash flow -5.92.
Financials

Questions about Ascentage Pharma Group International

Is Ascentage Pharma Group International (AAPG) overvalued?

At $11.97, Ascentage Pharma Group International's price is 421% above the $2.30 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Ascentage Pharma Group International's fair value?

Intrinsiqq's calculator puts Ascentage Pharma Group International's fair value at $2.30 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $1.72. Every input can be changed on the Intrinsic Value tab.

Is Ascentage Pharma Group International a high-quality business?

Ascentage Pharma Group International scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 5 checks computed from company filings. Its best check is revenue growth at 39.9%, and its weakest is return on capital at -36.0%. The Quality tab shows every check against its target.

Does Ascentage Pharma Group International (AAPG) pay a dividend?

No. Ascentage Pharma Group International (AAPG) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.1% buyback yield. The Dividends tab shows its cash returns.

Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing AAPG

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.